PL2837632T3 - Derivatives of triazabicyclo[3.2.1]octane useful for the treatment of proliferative diseases - Google Patents

Derivatives of triazabicyclo[3.2.1]octane useful for the treatment of proliferative diseases

Info

Publication number
PL2837632T3
PL2837632T3 PL13784533T PL13784533T PL2837632T3 PL 2837632 T3 PL2837632 T3 PL 2837632T3 PL 13784533 T PL13784533 T PL 13784533T PL 13784533 T PL13784533 T PL 13784533T PL 2837632 T3 PL2837632 T3 PL 2837632T3
Authority
PL
Poland
Prior art keywords
triazabicyclo
octane
derivatives
useful
treatment
Prior art date
Application number
PL13784533T
Other languages
Polish (pl)
Inventor
Yongzhi Cheng
Zhi Cheng
Min Zhou
Zhaojun Wang
Huizhen Li
Shenggang Fan
Original Assignee
Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd. filed Critical Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd.
Publication of PL2837632T3 publication Critical patent/PL2837632T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL13784533T 2012-04-13 2013-04-09 Derivatives of triazabicyclo[3.2.1]octane useful for the treatment of proliferative diseases PL2837632T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210109743 2012-04-13

Publications (1)

Publication Number Publication Date
PL2837632T3 true PL2837632T3 (en) 2017-01-31

Family

ID=49514204

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13784533T PL2837632T3 (en) 2012-04-13 2013-04-09 Derivatives of triazabicyclo[3.2.1]octane useful for the treatment of proliferative diseases

Country Status (7)

Country Link
US (1) US9090623B2 (en)
EP (1) EP2837632B1 (en)
JP (1) JP5925381B2 (en)
KR (1) KR101673979B1 (en)
CN (1) CN104334561B (en)
PL (1) PL2837632T3 (en)
WO (1) WO2013163917A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10398697B2 (en) 2014-09-04 2019-09-03 Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd. Solid solution comprising (6S)-5-methyl tetrahydrofolic acid or salt thereof, and preparation and use thereof
CN104490887A (en) * 2014-09-04 2015-04-08 连云港金康和信药业有限公司 Stable pharmaceutical composition of (6S)-5-methyl-calcium tetrahydrofolate

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124452A (en) * 1978-07-10 1992-06-23 Bioresearch S.P.A. Process for producing d,1-5-methyltetrahydrofolic acid and its salts
CH681303A5 (en) 1991-01-16 1993-02-26 Eprova Ag
DE4136921A1 (en) * 1991-11-11 1993-05-13 Knoll Ag METHOD FOR SEPARATING 5-METHYL-TETRAHYDROFOLIC ACID
CH686369A5 (en) 1994-05-09 1996-03-15 Eprova Ag Stable crystalline (6S) - and (6R) -Tetrahydrofolseure.
CH693905A5 (en) * 1999-04-15 2004-04-15 Eprova Ag Stable crystalline salts of 5-methyl tetrahydrofolic acid.
KR100551184B1 (en) 2001-05-14 2006-02-13 화이자 프로덕츠 인크. Tartrate Salts of 5,8,14-Triazatetracyclo[10.3.1.02,11.04,9]-Hexadeca-211,3,5,7,9-Pentaene and Pharmaceutical Compositions Thereof
CA2446988A1 (en) 2001-05-14 2002-11-21 Pfizer Products Inc. The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.02,11.04.9)-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
AU2002341327A1 (en) 2001-11-29 2003-06-10 Pfizer Products Inc. Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
MXPA04003807A (en) 2001-11-30 2004-07-30 Pfizer Prod Inc Pharmaceutical compositions of 5, 7, 14-triazatetracyclo [10.3.1.0(2,11).0(4,9)] -hexadeca -2(11) 3, 5, 7, 9-pentaene.
SE0303526D0 (en) * 2003-12-22 2003-12-22 Biofol Ab Chemotherapeutic agents
CN101143863B (en) 2006-09-13 2010-08-11 南京莱因医药科技有限公司 Resolution for 5-methyltetrahydrofolic acid and salifying method thereof
ES2536558T3 (en) 2008-12-11 2015-05-26 Cti Biopharma Corp. Citrate salt of 11- (2-pyrrolidin-1-yl-ethoxy) -14,19-dioxa-5,7,26-triaza-tetracycle [19.3.1.1 (2,6) .1 (8,12)] heptacosa -1 (25), 2 (26), 3,5,8,10,12 (27), 16,21,23-decene
CN101781637B (en) 2009-01-16 2012-09-05 中国科学院生物物理研究所 Human 5,10-methenyltetrahydrofolate and its compound crystallization methods, crystals and application thereof

Also Published As

Publication number Publication date
US20150065708A1 (en) 2015-03-05
CN104334561B (en) 2016-06-22
CN104334561A (en) 2015-02-04
KR101673979B1 (en) 2016-11-08
EP2837632B1 (en) 2016-05-18
JP2015513360A (en) 2015-05-11
US9090623B2 (en) 2015-07-28
EP2837632A1 (en) 2015-02-18
EP2837632A4 (en) 2015-10-14
WO2013163917A1 (en) 2013-11-07
JP5925381B2 (en) 2016-05-25
KR20140143437A (en) 2014-12-16

Similar Documents

Publication Publication Date Title
HUS1900040I1 (en) Macrocyclic derivatives for the treatment of proliferative diseases
HUS2200017I1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
IL231591A0 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
IL230635A (en) 1,2,3,4-tetrahydroquinoline derivative useful for the treatment of diabetes
LT2838539T (en) Estrogenic derivatives for use in the treatment of neurological disorders.
HK1192726A1 (en) 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases 124--5-
IL234796B (en) Compounds for the treatment of ischemia-reperfusion-related diseases
PL2837632T3 (en) Derivatives of triazabicyclo[3.2.1]octane useful for the treatment of proliferative diseases
HUP1100290A2 (en) Combination compositions for the treatment of proliferative diseases
HK1208454A1 (en) Pyrimidine derivatives for the treatment of bacterial diseases
PL399422A1 (en) Process for the preparation of 2&#39;-tetrahydroxydihydrochalcone
PL399423A1 (en) Process for the preparation of 2&#39;-hydroxydihydrochalcone
PL398695A1 (en) Process for the preparation of 2&#39;-hydroxydihydrochalcone